While the use of anti-IL-4/IL-13 receptor antibodies has shown dramatic response in the treatment of atopic dermatitis (11), the failure of an anti-IL-33 treatment has suggested that IL-33-ILC2 axis may not be central in the pathogenesis of the disease. This evidence concerns the gene IL33 and atopic eczema.